Overview

A Phase I Trial of HDFL48 in Recurrent or Metastatic Colorectal Cancers

Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
To determine the maximum tolerated dose and dose limiting toxicity of 5-FU and leucovorin with novel 48-hour infusion schedule, and to collect toxicity profile at different dose level of 5-FU/LV 48-hour infusion.
Phase:
Phase 1
Details
Lead Sponsor:
National Taiwan University Hospital
Treatments:
Fluorouracil
Leucovorin